Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (DE:LLY)
XETRA:LLY
Eloralintide
Overweight, Obesity
Phase III
Not Yet Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Jan 05, 2026
―
Imlunestrant, Imlunestrant + Goserelin, Tamoxifen 20 Mg, Pre-Filled Syringe
Breast Neoplasm Female
Phase II
Not Yet Recruiting
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Dec 11, 2025
Ly4064809
Healthy
Phase I
Active Not Recruiting
A Study of LY4064809 in Healthy Adult Chinese Participants
Nov 18, 2025
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Eli Lilly & Co (LLY) have in its pipeline
LLY is currently developing the following drugs: Eloralintide, Imlunestrant, Imlunestrant + Goserelin, Tamoxifen 20 Mg, Pre-Filled Syringe, Eloralintide. These drug candidates are in various stages of clinical development as the company works toward FDA approval.